Brooke was only three years old when she first learned about desmoid tumors. “My mother had six or seven,” she recalls.
In a report released yesterday, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Springworks Therapeutics (SWTX ...
Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.
Piper Sandler lowered the firm’s price target on Immunome (IMNM) to $21 from $23 and keeps an Overweight rating on the shares after the ...
2d
Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from ...
Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...
SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting ...
An analysis of SpringWorks Therapeutics, Inc., including recent FDA approval, promising sales, and future funding for ...
To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback